JP2014074724A5 - - Google Patents

Download PDF

Info

Publication number
JP2014074724A5
JP2014074724A5 JP2014006601A JP2014006601A JP2014074724A5 JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5 JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014006601 A JP2014006601 A JP 2014006601A JP 2014074724 A5 JP2014074724 A5 JP 2014074724A5
Authority
JP
Japan
Prior art keywords
cancer
subject
amount
biological sample
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014006601A
Other languages
English (en)
Japanese (ja)
Other versions
JP5615986B2 (ja
JP2014074724A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014074724A publication Critical patent/JP2014074724A/ja
Publication of JP2014074724A5 publication Critical patent/JP2014074724A5/ja
Application granted granted Critical
Publication of JP5615986B2 publication Critical patent/JP5615986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014006601A 2009-01-15 2014-01-17 Ｈｅｒ−２発現の測定による患者の反応を判定する方法 Active JP5615986B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US61/145,029 2009-01-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011546408A Division JP2012515353A (ja) 2009-01-15 2010-01-15 Ｈｅｒ−２発現の測定による患者の反応を判定する方法

Publications (3)

Publication Number Publication Date
JP2014074724A JP2014074724A (ja) 2014-04-24
JP2014074724A5 true JP2014074724A5 (https=) 2014-08-28
JP5615986B2 JP5615986B2 (ja) 2014-10-29

Family

ID=42340111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546408A Withdrawn JP2012515353A (ja) 2009-01-15 2010-01-15 Ｈｅｒ−２発現の測定による患者の反応を判定する方法
JP2014006601A Active JP5615986B2 (ja) 2009-01-15 2014-01-17 Ｈｅｒ−２発現の測定による患者の反応を判定する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011546408A Withdrawn JP2012515353A (ja) 2009-01-15 2010-01-15 Ｈｅｒ−２発現の測定による患者の反応を判定する方法

Country Status (12)

Country Link
US (3) US20100233732A1 (https=)
EP (1) EP2387717B1 (https=)
JP (2) JP2012515353A (https=)
KR (1) KR20110120890A (https=)
CN (1) CN102439452B (https=)
AU (1) AU2010204576A1 (https=)
BR (1) BRPI1007048A2 (https=)
CA (1) CA2749817A1 (https=)
ES (1) ES2526519T3 (https=)
IL (1) IL214067A0 (https=)
SG (1) SG172984A1 (https=)
WO (1) WO2010083463A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US8357277B2 (en) 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20120295259A1 (en) 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
FR2993668B1 (fr) * 2012-07-17 2015-07-03 Cisbio Bioassays Methode theranostique basee sur la detection de dimeres her2-her2
US20160041171A1 (en) * 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CN107003323B (zh) 2014-11-25 2019-06-04 文塔纳医疗系统公司 使用化学连接和半抗原转移的邻近测定法
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
WO2017161030A1 (en) 2016-03-15 2017-09-21 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
JP6922444B2 (ja) * 2016-11-11 2021-08-18 コニカミノルタ株式会社 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法
WO2019241599A1 (en) * 2018-06-14 2019-12-19 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
WO2020080891A1 (ko) * 2018-10-19 2020-04-23 주식회사 프로티나 유방암 재발 예측 방법
KR102936489B1 (ko) 2022-03-14 2026-03-09 부산대학교 산학협력단 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707440B2 (en) * 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
SE9601676D0 (sv) * 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US6335479B1 (en) * 1998-10-13 2002-01-01 Dai Nippon Printing Co., Ltd. Protective sheet for solar battery module, method of fabricating the same and solar battery module
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US20040248150A1 (en) * 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20030092012A1 (en) * 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US20030235832A1 (en) * 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6162593A (en) * 1999-10-26 2000-12-19 Wyatt; Marion F. Diisopropylbenzene containing solvent and method of developing flexographic printing plates
DE19963849A1 (de) * 1999-12-30 2001-07-12 Giesecke & Devrient Gmbh Datenträger mit gedrucktem Sicherheitselement
US7306904B2 (en) * 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) * 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US20030207300A1 (en) * 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7160735B2 (en) * 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US6630296B2 (en) * 2000-08-08 2003-10-07 Aclara Biosciences, Inc. Multiplexed enzymatic assays
EP1236740B1 (de) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US7041459B2 (en) * 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
CA2445053A1 (en) * 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2002097112A2 (en) * 2001-05-26 2002-12-05 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
WO2003055439A2 (en) * 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
US20040241688A1 (en) * 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
WO2003033741A1 (en) * 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
US6659577B2 (en) * 2001-12-06 2003-12-09 Hewlett-Packard Development Company, L.P. Dual flat springs for tool-less slide installation
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ATE480564T1 (de) * 2002-02-26 2010-09-15 Sigma Tau Ind Farmaceuti Monoklonaler anti-mensch-tenascin-antikörper
JP2006509183A (ja) * 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
JP2005521885A (ja) * 2002-04-02 2005-07-21 アクララ バイオサイエンシーズ， インコーポレイテッド 電気泳動的に分離される分子タグを使用する多重化アッセイ
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20090111127A1 (en) * 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040175765A1 (en) * 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4443407B2 (ja) * 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2493671A1 (en) * 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
EP1613205B1 (en) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
EP1653986A4 (en) * 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
EP1664716A4 (en) * 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US20050106571A1 (en) * 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
WO2006044748A2 (en) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
DK1842226T3 (da) * 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) * 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
US8357277B2 (en) * 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (zh) * 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3

Similar Documents

Publication Publication Date Title
JP2014074724A5 (https=)
Schneider et al. PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis–impact on clinical outcome
Chua et al. Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review
JP5615986B2 (ja) Ｈｅｒ−２発現の測定による患者の反応を判定する方法
JP2012515353A5 (https=)
Tran et al. Luminal-B breast cancer and novel therapeutic targets
Shibuya et al. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma
Spears et al. In situ detection of HER2: HER2 and HER2: HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
US10416162B2 (en) Her2 diagnostic methods
Koutras et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
Gruber et al. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry
JP2016517960A5 (https=)
JP2016536568A5 (https=)
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
Augustin et al. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer
Monteiro et al. Phosphorylated EGFR at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas
Li et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis
Akagi et al. Visinin‐like protein‐1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients
Ramić et al. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer
JP6626037B2 (ja) 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
Talla et al. Immuno‐oncology gene expression profiling of formalin‐fixed and paraffin‐embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing
Sato et al. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2
Miyai et al. Frequent EGFR expression/EGFR amplification and lack of activating mutation in testicular choriocarcinoma
Yu et al. Evaluation of expression of the Wnt signaling components in canine mammary tumors via RT2 Profiler PCR Array and immunochemistry assays
Martín-Algarra et al. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology